Factors associated with HIV RNA viral non-suppression among children and adolescents with HIV attending public health facilities in Gulu City, Uganda: a retrospective cohort study

Read full text
Authors: Ventrina Lanyero, Felix Bongomin, Daniel Ebbs, Ritah Nantale, Emmanuel Ochola
Cited by: 1
References: 25

Abstract

Background: Human immunodeficiency virus (HIV) RNA viral load testing is the gold standard for monitoring antiretroviral therapy (ART), and sustained viral suppression is critical for preventing HIV-related morbidity and transmission. However, children and adolescents with HIV (CAWH) often experience lower viral suppression rates than adults. Data on the incidence of HIV RNA viral non-suppression and its determinants among CAWH in northern Uganda remain limited. Objectives: To determine the incidence and factors associated with HIV RNA viral load non-suppression among CAWH receiving ART in Gulu City, Uganda. Design: Retrospective cohort study. Methods: We reviewed records of CAWH receiving ART at public health facilities in Gulu City. Data were abstracted for HIV RNA viral load outcomes at 6, 12, 18, and 24 months and at the most recent follow-up. The primary outcome was HIV RNA viral non-suppression during follow-up. Bivariable and multivariable Cox proportional hazards regression models were used to identify factors associated with viral load non-suppression. Adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were reported. Results: Among 218 participants, the median age was 12.5 years (interquartile range (IQR), 7-18), and 153 (70.2%) were female. During follow-up, 99 participants (45.4%) experienced viral load non-suppression. The incidence rate of viral load non-suppression was 25.6 cases per 100 person-years. Factors independently associated with non-suppression included age

Fields of Study & Subjects

HIV/AIDS Research and Interventions HIV Research and Treatment HIV/AIDS drug development and treatment

Publication details

Journal / source
Therapeutic Advances in Infectious Disease
Publisher
SAGE Publications
Volume
13
Pages
20499361261448464–20499361261448464
Publication date
1 May 2026
Language
EN